Skip to Main Content

Paper Details

GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
J Immunother Cancer
4
2022
Author NameAffiliation
Daniel MartinezThe Children's Hospital of Philadelphia
Daniel MartinezThe Children's Hospital of Philadelphia
Dimiter S DimitrovUniversity of Pittsburgh School of Medicine
Kristopher R BosseDivision of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia
Kristopher R BosseUniversity of Pennsylvania Perelman School of Medicine
  • 1 - 5

Datasets

Release 1.2